早产儿视网膜病变玻璃体腔注射贝伐珠单抗治疗后的神经发育结局:前瞻性病例对照研究
该前瞻性病例对照研究纳入148例早产儿,分为无ROP史组(0组)、有ROP史未治疗组(1组)和接受单次玻璃体腔注射贝伐珠单抗0.625mg的ROP组(2组),在1至3岁时评估眼发育和Bayley III神经发育。调整胎龄及全身危险因素后,三组神经发育无显著差异;2组与1组在屈光状态、眼轴长度和Cardiff视力上无显著差异,但2组较0组球镜等效更近视、Cardiff视力更差。
要点
- 调整胎龄等全身危险因素后,三组间Bayley III神经发育评分无显著差异。
- 2组与1组在屈光状态、眼轴长度和Cardiff视力上无显著差异。
- 2组较0组球镜等效更近视且Cardiff视力更差,1组和2组柱镜度均大于0组。
核心结论
- 在平均1.5岁时,有IVB史(2组)的儿童与无需治疗的ROP早产儿(1组)相比,屈光和视觉结局及神经发育结局相似,尽管本研究可能未检测到小的但临床显著的差异。
研究设计与样本
- 前瞻性病例对照研究,纳入148例早产儿(85男63女),分为无ROP史组(0组)、有ROP史未治疗组(1组)和接受单次IVB 0.625mg的ROP组(2组)。
- 在1至3岁时进行睫状肌麻痹验光、眼轴长度、Cardiff视力及Bayley婴幼儿发育量表第三版(Bayley III)神经发育评估,并比较组间差异。
主要发现
- 评估时平均年龄1.49±0.59岁。
- 0组胎龄、出生体重和Apgar评分显著高于1组和2组。
- 1组与2组除2组胎龄较低外,人口学和全身危险因素无显著差异。
- 1组和2组柱镜度显著大于0组;2组球镜等效较0组显著更近视,Cardiff视力较0组显著更差。
- 1组与2组在屈光状态、眼轴长度和Cardiff视力上无显著差异;调整胎龄和其他全身危险因素后,三组Bayley III各领域评分及不良神经发育结局风险均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出可能存在小的但临床显著的差异而本研究未能检测到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the neurodevelopmental and ocular developmental outcomes in premature children who have undergone intravitreal bevacizumab injection (IVB) for treatment of type 1 retinopathy of prematurity (ROP). DESIGN: Prospective case-control study. PARTICIPANTS: We enrolled 3 groups of premature patients: premature children who had no history of ROP (group 0), premature children with history of ROP without treatment (group 1), and premature children with ROP who had received a single IVB (0.625 mg; group 2). METHODS: Ocular developmental assessment, including cycloplegic refractometry, axial length, Cardiff acuity, and neurodevelopmental assessment via the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley III), were performed at 1 to 3 years of age and were compared between groups. MAIN OUTCOME MEASURES: Ocular developmental outcomes and Bayley III scores. RESULTS: A total of 148 patients (85 boys and 63 girls) were included. The mean age at assessment was 1.49±0.59 years. Group 0 patients demonstrated significantly higher gestational age (GA), birth weight, and Apgar scores compared with group 1 and 2 patients. There were no significant differences between groups 1 and 2 in demographics or systemic risk factors except for lower GA in group 2. The cylindrical power was significantly larger in groups 1 and 2 compared with group 0. The spherical equivalent was significantly more myopic and the Cardiff acuity was significantly poorer in group 2 than in group 0. There were no significant differences between groups 1 and 2 in refractive status, axial length, or Cardiff acuity. Neurodevelopmental assessment using Bayley III showed no significant difference among the 3 groups in any aspect after adjusting for GA and other systemic risk factors. The risks for poor neurodevelopmental outcomes also were not significantly different. CONCLUSIONS: At the mean age of 1.5 years, children with prior history of IVB (group 2) showed similar refractive and visual outcomes and similar neurodevelopmental outcomes compared with premature patients with ROP without requirement of treatment (group 1), although there is a possibility that a small but clinically significant difference may not have been detected in the current study.
引用
- Fan YY, Huang YS, Huang CY, et al. Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study. Ophthalmology. 2019. PMID: 30954553. doi:10.1016/j.ophtha.2019.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。